Tango Therapeutics (TNGX) Asset Utilization Ratio (2021 - 2026)
Tango Therapeutics (TNGX) recorded quarterly Asset Utilization Ratio of 0.14 in Q1 2026, down 33.35% quarter-over-quarter from 0.2 in Q4 2025, and down 1.57% on a YoY basis from 0.14 in Q1 2025.
Tango Therapeutics (TNGX) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Tango Therapeutics' Asset Utilization Ratio history runs 6 years deep, the most recent figure standing at 0.14 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio fell 1.57% year-over-year to 0.14; the TTM figure through Mar 2026 stood at 0.14 (down 1.57% YoY), while the FY2025 annual figure was 0.17, up 49.09% from the prior year.
- Asset Utilization Ratio was 0.14 for Q1 2026 at Tango Therapeutics, down from 0.2 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.3 in Q3 2025 to a low of 0.05 in Q2 2022.
- Historically, Asset Utilization Ratio has averaged 0.11 across 5 years, with a median of 0.09 in 2023.
- The sharpest annual moves came in 2022 and 2025: Asset Utilization Ratio plunged 79.1% in 2022, then jumped 151.08% in 2025.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.06 in 2022, then jumped by 59.29% to 0.09 in 2023, then surged by 43.04% to 0.13 in 2024, then surged by 62.92% to 0.2 in 2025, then tumbled by 33.35% to 0.14 in 2026.
- The last three Asset Utilization Ratio figures came in at 0.14 (Q1 2026), 0.2 (Q4 2025), and 0.3 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | 0.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.14 |
| Dec 31, 2025 | 0.20 |
| Sep 30, 2025 | 0.30 |
| Jun 30, 2025 | 0.09 |
| Mar 31, 2025 | 0.14 |
| Dec 31, 2024 | 0.13 |
| Sep 30, 2024 | 0.12 |
| Jun 30, 2024 | 0.11 |
| Mar 31, 2024 | 0.09 |
| Dec 31, 2023 | 0.09 |
| Sep 30, 2023 | 0.09 |
| Jun 30, 2023 | 0.09 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | 0.06 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | 0.05 |
| Mar 31, 2022 | 0.07 |
| Dec 31, 2021 | 0.07 |
| Sep 30, 2021 | 0.11 |
| Jun 30, 2021 | 0.25 |